Table 1. Characteristics of included studies.

references	No. of patients in meta-analysis (case/control)	Age (year)	histology	setting	Status at randomization	Prior therapy	maintenance	End-point	Median follow-up (month)
Habermann(2006)	415(207/208)	60–92	DLBCL	untreated	CR/PR	CHOP or R-CHOP	375 mg/m2/w X 4w every 6 mo for 2 y	FFS/ OS	40
Haioun(2009)	269 (139/130)	18–60	DLBCL/other high grade lymphoma	untreated	CR,/CRu /PR	ACVBP or AC/ACE 4 courses & ASCT	375 mg/m2/w X4w	EFS	48
Gisselbrecht(2012)	242(122/120)	18–65	DLBCL	Relapsed/Refractory	CR/CRu/PR (before ASCT)	R-ICE or R-DHAP & ASCT	375 mg/m2 every 8weeks for 1y	EFS/ OS	44
Jaeger(2015)	662(329/333)	>18	DLBCL/follicular lymphoma grade 3b	untreated	CR/CRu	R 8 courses & CHOP-like 4 to 8 courses	375mg/m2 every2 months for 6 doses or 12 doses (amendment)	EFS/ OS	45
Harig(2015)	152(77/75)	>18	DLBCL	Untreated/ Relapsed/Refractory	CR/PR	R-CHOP or other	375 mg/m2 every 3 months for 2 y	RFS/ OS	32